Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes

Annals of Surgical Oncology

Volumn 24, Issue 2, 2017, Pages 407-417

  Fracol, Megan ^a   Datta, Jashodeep ^a   Lowenfeld, Lea ^a   Xu, Shuwen ^a   Zhang, Paul J ^a   Fisher, Carla S ^a   Czerniecki, Brian J ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DISEASE; CANCER RECURRENCE; CANCER TISSUE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; TH1 CELL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; AGED; BREAST TUMOR; CARCINOGENESIS; DRUG EFFECTS; FOLLOW UP; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; SURVIVAL RATE; TH1 CELLS;

EID: 84988729307     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5584-6     Document Type: Article

References (38)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe H, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168–83.
2. Wang GS, Zhu H, Bi SJ. Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Rep. 2012;6(4);779–82.
3. Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2078–99.
4. Datta J, Rosemblit C, Berk E, et al. Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 2015;4(10):e1022301. Ecollection 2015 Oct
5. Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, et al. Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res. 2015; 17:71.
6. Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, et al. Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring. JAMA Oncol. 2016; 2(2):242–6.
7. Sharma A, Koldovsky U, Xu S, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact DCIS. Cancer. 2012;118(17):4354–62.
8. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012;35(1):54–65.
9. Czopek J, Pawlega J, Fijorek K, Puskulluoglu M, Rozanowski P, Okori K. HER-3 expression in HER-2-amplified breast carcinoma. Contemp Oncol. 2013;17(5):446–9.
10. Bae SY, La Choi Y, Kim S, et al. HER-3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat. 2013;139(3):741–50.
11. Jhaveri K, Esteva FJ. Pertuzumab in the treatment of HER-2+ breast cancer. J Natl Compr Canc Netw. 2014;12(4):591–8.
12. Harbeck N, Beckmann MW, Rody A, et al. HER-2 dimerization inhibitor pertuzumab- mode of action and clinical data in breast cancer. Breast Care. 2013;8(1):49–55.
13. Giltnane JM, Moeder C, Camp RL, Rimm D. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer. 2009:115(11):2400–9.
14. Bae SY, Choi YL, Kim S, Kim M, Kim J, Yung SP, et al. Her-3 status by immunohistochemistry is correlated with poor-prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat. 2013;139:741–750.
15. Karamouzis M, Dalagiorgou G, Georgopoulou U, Nonni A, Kontos M, Papvassiliou A. HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas. Oncotarget. 2015;7(5):5576–97.
16. Moi L, Flageng M, Gjerde J, Madsen A, Rost T, Gudbrandsen O, et al. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 2012;12:247.
17. Datta J, Xu S, Terhune JH, Rosemblit C, Berk E, Fitzpatrick E, et al. Novel strategy to identify MHC class II-promiscuous CD4+ peptides from tumor antigens for utilization in vaccination [abstract]. J Immunother Cancer. 2014;2 Suppl 3:P47.
18. Boshoff C, Weiss R. AIDS-related malignancies. Nature Rev Cancer. 2002:2;373–82.
19. Sheil AG. Cancer after transplantation. World J Surg. 1986;10:389–96.
20. Penn I. Malignant melanoma in organ allograft recipients.Transplantation. 1996;61:274–8.
21. Penn, I. Sarcomas in organ allograft recipients. Transplantation. 1995;60:1485–91.
22. Alokail MS, Al-Daghri NM, Mohammed AK, Vanhoutte P, Alenad A. Increased TNF alpha, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients. Med Oncol. 2014;31:38.
23. Jia Y, Xu L, Lin Q, Zhu M, Ding L, Wu K, et al. Levels of lymphocyte subsets in peripheral blood prior to treatment are associated with aggressive breast cancer phenotypes or subtypes. Med Oncol. 2014;31:981.
24. Matsumoto H, Koo S, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol. 2015;68(7):506–10.
25. Schmidt G, Meyberg-Solomayer G, Gerlinger C, Juhasz-Boss I, Herr D, Rody A, et al. Identification of prognostic different subgroups in triple negative breast cancer by HER2-neu protein expression. Arch Gynecol Obstet. 2014;290:1221–9.
26. Li Q, Yuan Z, Cao B. The function of human epidermal growth factor receptor-3 and its role in tumors. Oncol Rep. 2013;30:2563–70.
27. Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012;31: 706–15.
28. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105(4):266–73.
29. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immune-surveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.
30. Idirisinghe PKA, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Am J Clin Pathol. 2010;133:416–29.
31. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP, et al. Changes in estrogen receptor, progesterone receptor and HER-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 2009;29:1557–62.
32. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20:1953–8.
33. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–41.
34. Frogne T, Benjaminsen RV, Sonne-Hansen K, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 2009;114:263–75.
35. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto- oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953–62.
36. Clendenen TV, Kim S, Moy L, Wan L, Rusinek H, Stanczyk FZ, et al. Magnetic resonance imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magn Reson Imaging. 2013;31:1–9.
37. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries L, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):1–8.
38. Aapro M, Wildiers H. Triple negative breast cancer in the older population. Ann Oncol. 2012;23(6):vi52–5.